HIV and Aging: Effects on the Central Nervous System

Abstract

With the introduction of combination antiretroviral therapy, many human immunodeficiency virus-positive (HIV+) individuals are reaching advanced age. The proportion of people living with HIV older than 50 years already exceeds 50% in many communities, and is expected to reach this level nationally by 2015. HIV and aging are independently associated with neuropathological changes, but their concurrence may have a more deleterious effect on the central nervous system (CNS). Published data about neurocognitive and neuroimaging markers of HIV and aging are reviewed. Putative factors contributing to neurocognitive impairment and neuroimaging changes in the aging HIV+ brain, such as metabolic disturbances, cardiovascular risk factors, immune senescence, and neuroinflammation, are described. The possible relationship between HIV and some markers of Alzheimer's disease is presented. Current research findings emphasize multiple mechanisms related to HIV and combination antiretroviral therapy that compromise CNS structure and function with advancing age.

Keywords

human immunodeficiency virus - aging - neurocognitive - neuroimaging - metabolic syndrome

• References

• 1 Bhaskaran K, Mussini C, Antinori A , et al; CASCADE Collaboration. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63 (2) 213-221
• 2 Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry 2008; 20 (1) 73-88
• 3 McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic?. AIDS 2010; 24 (9) 1367-1370
• 4 Soontornniyomkij V, Achim C. Aging. In: Gendelman HE, Grant I, Everall PE, , et al, eds. The neurology of AIDS. 3rd edition. New York: Oxford Univeristy Press; 2012: 567-580
• 5 Rodriguez-Penney AT, Iudicello JE, Riggs PK , et al; HIV Neurobehavioral Research Program HNRP Group. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS 2013; 27 (1) 5-16
• 6 Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005; 19 (4) 407-411
• 7 Khanlou N, Moore DJ, Chana G , et al; HNRC Group. Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol 2009; 15 (2) 131-138
• 8 Worm SW, Lundgren JD. The metabolic syndrome in HIV. Best Pract Res Clin Endocrinol Metab 2011; 25 (3) 479-486
• 9 Ciccarelli N, Fabbiani M, Di Giambenedetto S , et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76 (16) 1403-1409
• 10 Schweinsburg BC, Taylor MJ, Alhassoon OM , et al; HNRC Group. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005; 11 (4) 356-364
• 11 Liner J, Meeker RB, Robertson K. CNS toxicity of antiretroviral drugs. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010: San Francisco, CA.
• 12 Heaton RK, Clifford DB, Franklin Jr DR , et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75 (23) 2087-2096
• 13 Antinori A, Arendt G, Becker JT , et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69 (18) 1789-1799
• 14 Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56 (7) 1004-1017
• 15 Bhatia R, Ryscavage P, Taiwo B. Accelerated aging and human immunodeficiency virus infection: emerging challenges of growing older in the era of successful antiretroviral therapy. J Neurovirol 2012; 18 (4) 247-255
• 16 Hardy DJ, Vance DE. The neuropsychology of HIV/AIDS in older adults. Neuropsychol Rev 2009; 19 (2) 263-272
• 17 Valcour V, Shikuma C, Shiramizu B , et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63 (5) 822-827
• 18 Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 2004; 18 (Suppl. 01) S11-S18
• 19 Cherner M, Ellis RJ, Lazzaretto D , et al; HIV Neurobehavioral Research Center Group. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18 (Suppl. 01) S27-S34
• 20 Morgan EE, Iudicello JE, Weber E , et al; HIV Neurobehavioral Research Program (HNRP) Group. Synergistic effects of HIV infection and older age on daily functioning. J Acquir Immune Defic Syndr 2012; 61 (3) 341-348
• 21 MacDonald SW, Hultsch DF, Dixon RA. Performance variability is related to change in cognition: evidence from the Victoria Longitudinal Study. Psychol Aging 2003; 18 (3) 510-523
• 22 Morgan EE, Woods SP, Delano-Wood L, Bondi MW, Grant I ; HIV Neurobehavioral Research Program (HNRP) Group. Intraindividual variability in HIV infection: evidence for greater neurocognitive dispersion in older HIV seropositive adults. Neuropsychology 2011; 25 (5) 645-654
• 23 van Gorp WG, Miller EN, Marcotte TD , et al. The relationship between age and cognitive impairment in HIV-1 infection: findings from the Multicenter AIDS Cohort Study and a clinical cohort. Neurology 1994; 44 (5) 929-935
• 24 Vance DE, Wadley VG, Crowe MG, Raper JL, Ball KK. Cognitive and everyday functioning in older and younger adults with and without HIV. Clin Gerontol 2011; 34 (5) 413-426
• 25 Sacktor N, Skolasky RL, Cox C , et al; Multicenter AIDS Cohort Study (MACS). Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus. J Neurovirol 2010; 16 (5) 335-341
• 26 Cysique LA, Maruff P, Bain MP, Wright E, Brew BJ. HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 2011; 23 (1) 83-89
• 27 Wilkie FL, Goodkin K, Khamis I , et al. Cognitive functioning in younger and older HIV-1-infected adults. J Acquir Immune Defic Syndr 2003; 33 (Suppl. 02) S93-S105
• 28 Onen NF, Overton ET, Seyfried W , et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11 (2) 100-109
• 29 Valcour V, Paul R, Neuhaus J, Shikuma C. The effects of age and HIV on neuropsychological performance. J Int Neuropsychol Soc 2011; 17 (1) 190-195
• 30 Becker JT, Maruca V, Kingsley LA , et al; Multicenter AIDS Cohort Study. Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology 2012; 54 (2) 113-121
• 31 Towgood KJ, Pitkanen M, Kulasegaram R , et al. Mapping the brain in younger and older asymptomatic HIV-1 men: frontal volume changes in the absence of other cortical or diffusion tensor abnormalities. Cortex 2012; 48 (2) 230-241
• 32 Ances BM, Ortega M, Vaida F, Heaps J, Paul R. Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr 2012; 59 (5) 469-477
• 33 Pfefferbaum A, Rosenbloom MJ, Sassoon SA , et al. Regional brain structural dysmorphology in human immunodeficiency virus infection: effects of acquired immune deficiency syndrome, alcoholism, and age. Biol Psychiatry 2012; 72 (5) 361-370
• 34 Stout JC, Ellis RJ, Jernigan TL , et al; HIV Neurobehavioral Research Center Group. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. Arch Neurol 1998; 55 (2) 161-168
• 35 Chang L, Andres M, Sadino J , et al. Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage 2011; 58 (4) 1017-1027
• 36 Chen Y, An H, Zhu H , et al. White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients. Neuroimage 2009; 47 (4) 1154-1162
• 37 Chang L, Wong V, Nakama H , et al. Greater than age-related changes in brain diffusion of HIV patients after 1 year. J Neuroimmune Pharmacol 2008; 3 (4) 265-274
• 38 Gongvatana A, Cohen RA, Correia S , et al. Clinical contributors to cerebral white matter integrity in HIV-infected individuals. J Neurovirol 2011; 17 (5) 477-486
• 39 Chang L, Ernst T, Leonido-Yee M , et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999; 53 (4) 782-789
• 40 Holt JL, Kraft-Terry SD, Chang L. Neuroimaging studies of the aging HIV-1-infected brain. J Neurovirol 2012; 18 (4) 291-302
• 41 Chang L, Lee PL, Yiannoutsos CT , et al; HIV MRS Consortium. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004; 23 (4) 1336-1347
• 42 Harezlak J, Buchthal S, Taylor M , et al; HIV Neuroimaging Consortium. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011; 25 (5) 625-633
• 43 Cysique LA, Moffat K, Moore DM , et al. HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS ONE 2013; 8 (4) e61738
• 44 Ernst T, Jiang CS, Nakama H, Buchthal S, Chang L. Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging 2010; 32 (5) 1045-1053
• 45 Orringer DA, Vago DR, Golby AJ. Clinical applications and future directions of functional MRI. Semin Neurol 2012; 32 (4) 466-475
• 46 Thomas JB, Brier MR, Snyder AZ, Vaida FF, Ances BM. Pathways to neurodegeneration: effects of HIV and aging on resting-state functional connectivity. Neurology 2013; 80 (13) 1186-1193
• 47 Ances BM, Vaida F, Yeh MJ , et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis 2010; 201 (3) 336-340
• 48 Ernst T, Yakupov R, Nakama H , et al. Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol 2009; 65 (3) 316-325
• 49 Chang L, Holt JL, Yakupov R, Jiang CS, Ernst T. Lower cognitive reserve in the aging human immunodeficiency virus-infected brain. Neurobiol Aging 2013; 34 (4) 1240-1253
• 50 Krishnan S, Schouten JT, Atkinson B , et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr 2012; 61 (3) 381-389
• 51 Boden-Albala B, Sacco RL, Lee HS , et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008; 39 (1) 30-35
• 52 Valcour VG, Sacktor NC, Paul RH , et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging with HIV cohort. J Acquir Immune Defic Syndr 2006; 43 (4) 405-410
• 53 Valcour VG, Shikuma CM, Shiramizu BT , et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 38 (1) 31-36
• 54 McCutchan JA, Marquie-Beck JA, Fitzsimons CA , et al; CHARTER Group. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012; 78 (7) 485-492
• 55 Nakamoto BK, Jahanshad N, McMurtray A , et al. Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals. J Neurovirol 2012; 18 (4) 303-312
• 56 Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009; 4 (2) 163-174
• 57 Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005; 19 (2) 127-135
• 58 Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005; 65 (9) 1490-1492
• 59 Clifford DB, Fagan AM, Holtzman DM , et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009; 73 (23) 1982-1987
• 60 Gisslén M, Krut J, Andreasson U , et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 2009; 9: 63
• 61 Ances BM, Christensen JJ, Teshome M , et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology 2010; 75 (2) 111-115
• 62 Ances BM, Benzinger TL, Christensen JJ , et al. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol 2012; 69 (1) 72-77
• 63 Valcour VG. HIV, aging, and cognition: emerging issues. Top Antivir Med 2013; 21 (3) 119-123
• 64 Jahanshad N, Valcour VG, Nir TM , et al. Disrupted brain networks in the aging HIV+ population. Brain Connect 2012; 2 (6) 335-344
• 65 Morgan EE, Woods SP, Letendre SL , et al; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol 2013; 19 (2) 150-156
• 66 Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis 2010; 9: 8
• 67 Wendelken LA, Valcour V. Impact of HIV and aging on neuropsychological function. J Neurovirol 2012; 18 (4) 256-263
• 68 Becker JT, Kingsley L, Mullen J , et al; Multicenter AIDS Cohort Study. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73 (16) 1292-1299
• 69 Wright EJ, Grund B, Robertson K , et al; INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75 (10) 864-873
• 70 Foley J, Ettenhofer M, Wright MJ , et al. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol 2010; 24 (2) 265-285
• 71 Fabbiani M, Ciccarelli N, Tana M , et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med 2013; 14 (3) 136-144